Member Info for Skippysb01

Volume is up this morning. SP holding really well at this level. Ask over 210.

Absolutely no chance of another RNS before Xmas. :-)

It says 2. A glitch I have seen before on LSE.

Nice RNS. Not game changing but setting up for a sale of Phasefocus next year which could be significant now.

Amagedon21 - I’m happy for you do say we won’t get another RNS this year if that summons another one! I didn’t think.we would get one now either…

I believe the JORCS have all been commissioned at the same time so will probably be a series of RNS like this.

I would like to know how many JORCS there will be and for what. I did expect one JORC for all but perhaps I wasn’t paying attention.

This does look like a big resource update so very welcome.

Ah OK. I saw the bid hit 209 for a very short time but fair enough. Could be a sell then.

210p is going to tempt a few and who can blame them. If you are trading this you could have accumulated those shares over the last few weeks and made a good 10% on that trade.

It's almost certainly a buy. At 210p there has not been an opportunity to sell at that price. So a buy worked on throughout the day and late reported. IMO.

Unless anyone can see otherwise?

I'm more or less certain the SNG have stated previously that they absolutely are talking to the regulatory bodies about EUA.

You can assume that all of the forms are filled in and the application is anticipated but it needs P3 outcomes stapled to the form as such to actually progress through the EUA process. It's the efficacy of the drug demonstrated via trial that dictates the EUA outcome, the science behind it, regardless of how good it is, isn't enough on it's own.

I'm no chartist but todays chart looks perfect. Steady climb. Strong volume at the ask. Strap in.

210 paid. Not a small trade either - 22k

I still think there is a significant upside to the SP to come ahead of the P3 readout. Most of us on here are longer term investors and we have already decided / have averages significantly lower that todays SP etc so we have very little reason to change our position unless something unexpected changes.

However - particularly in AIM - speculation is king. So much money gets invested just ahead of an 'event' especially where there are good odds of a quick return. I expect this share becomes irresistible to a lot of shorter term investors the closer we get to the big one. Nobody knows exactly when the big one will drop but the tension starts to rise after this week.

Logic tells me it will be second week of Jan before we get the big one but the market (and some of us for that matter) have already started to sense something could happen before that.

The great thing about this share now is that we now get to watch this happen over a fairly short period of time. So we can say this or that about what we think will happen and find out if we are right. Most of us are on the same side and I like to think that whilst we don't always agree - we are violently agreeing on where we hope this might end up.

Amagedon21. True. The versatility of the test kit provides extra interest for investors. Being able to provide an inexpensive solution for a range of conditions adds huge value to the IP.

PremiernLeague clubs told all staff and players must do a lateral flow test every day. In the news this morning. So that’s 40% accurate if you have symptoms and 70% accurate if you have symptoms!

So many markets for the Paraytec test because it’s so much better!

It will update when the market opens. It can be glitchy.

Yesterday afternoon, for about 10 mins, the bid was showing on a number of platforms as 218 with ask well below that, which makes no sense at all. A glitch that some reported on here. Always do dummy trades to get a better idea of what the spread really looks like.

Loving Dr Whitesmile! I note that RM has been looking increasingly like Father Christmas as we approach the big moment!

I saw that on HL. A glitch? but did make me dribble my coffee slightly....

They don't have to RNS data unblinding as they have already RNS'd last patient dosed and that top line data will be early next year.

I do think though that the unblinding can be mentioned by RM in an interview because it isn't material enough require an RNS. So I think he will mention it.

Do we really think that Paraytec close down for the university break? Granted Paraytec employees will have holidays over Xmas anyway but I doubt it closes down for weeks.

Sometimes it's best to focus on that. It's looking very strong for the rest of December...... !!

sparkyboy1 - I don't think it is/ Analysis of the data is complex. However I do keep asking myself what would happen if the data showed SNG to be very very effective and how obvious that would be on opening the data up.... I suspect they just stick to strict protocol until it's all done.

I asked because I think the next test for the SP is when the trial is unblinded and we are waiting for the 35 day readout. i.e. the market will become more focussed because the RNS (the big one) could come 'any day'. Clearly more likely early 2022 but who would want to be out.......